The market appears to price FHN as a commodity regional balance sheet rather than a premium franchise, consistent with its 12.30 trailing P/E and 10.79 forward P/E. Relative to peers such as FITB at 1.65 P/B and CMA at 1.53, the multiple looks undemanding, though the price-to-tangible-book gap should be read alongside the recent swing to negative ROE. Investors should monitor whether earnings normalize after reserve releases, since the trailing P/E may be flattered by provision reversals.

With equity at roughly 11% of assets, the leverage component is modest, so ROE is driven mainly by ROA, which itself is compressed. The decline into negative territory in 2026Q3 coincides with a 130.0% efficiency ratio, suggesting revenue weakness rather than cost control drove the result. Investors should monitor whether the reported 2026Q1 profitability was repeatable once reserve releases normalize.

The stable NIM suggests funding costs and asset yields have moved in step, so margin compression is not the source of the deterioration. The efficiency spike is better explained by a sharp fall in non-interest income, with fee share turning negative in 2026, rather than cost escalation. This warrants further investigation into the composition of fee revenue before assuming operating leverage will recover.

A steady equity-to-assets ratio alongside growing total assets suggests capital has kept pace with balance sheet expansion, which is a constructive but incomplete read. Without regulatory capital ratios, the capacity for buybacks and dividends cannot be sized against minimums. Investors should obtain the CET1 trajectory before concluding on capital return capacity.